Stereotactic radiosurgery provided clinicians the ability to administer high single-doses of radiation to intracranial targets with relative safety. Analysis of clinical outcome from radiosurgery calfs into question some of the radiobiological principles that have guided conventional fractionated radiotherapy in the past. The response of the tumor or target tissue being irradiated, as welf as the response of the surrounding normal tissue, seems predominantly determined by the tumor or target vasculature. Injury to the tumor or target vasculature appears to contribute to the probability of developing normal tissue complications.
Introduction
Prior to the advent of radiosurgery, almost all clinical radiation therapy to intracranial targets was fractionated. Radiation Oncology residents are taught the principle that fractionating therapeutic radiation to a tumor causes less injury to normal tissue than the tumor itself. This is based on survival radiobiological studies of a few cell culture lines of fast-growing malignant tumors and analysis of clinical experience with some common fast-growing malignant tumors commonly treated with fractionated radiotherapy in the clinic. Because slow-growing benign tumors have been notoriously difficult to study in cell culture or animal models, their radiobiological responses and how they change with different fractionation are poorly defined. Prior to the advent of radiosurgery, few radiation oncologists had more than limited experience in treating with high doses of single-fraction radiation. Stereotactic radiosurgery provided clinicians with the ability to administer high single-doses of radiation to intracranial targets with relative safety, Radiosurgery ushered in a new era of understanding of how different approaches to radiation treatment planning and radiobiology may be modified in the clinic to achieve goals previously thought unreachable.
Optimization of any clinical intervention (radiation, drug therapy, or surgery) requires equal attention to maximizing the desired outcome (tumor cure, vascular malformation obliteration, etc.) and to minimizing complications. This can be understood by the concept of paired dose-response curves for cure (tumor control or AVM obliteration) and complications as shown in Figure I . Radiosurgery exploits the radiobiological principle that small volumes of normal tissue irradiated to significant doses (such as in a radiosurgery treatment plan) can withstand much higher doses of radiation than larger volumes of normal tissue (such as when standard, non-stereotactic radiotherapy is used, where minimum margins are usually 10-15 mm). Reducing the volume of tissue irradiated can shift the complication dose-response curve down and to the right compared to treatment of a larger volume when a margin of surrounding normal tissue is included, thereby increasing the therapeutic window between cure and complications. A full understanding of radiosurgery requires knowledge of the underlying radiobiological principles affecting desired radiation effects and complications. complications. The two separate complications curves for radiation treatment to a target with a 15-mm margin and for radiosurgical treatment using no margin indicate how radiosurgery can reduce complications for the same treatment dose (second arrow at 20 Gy pointing downwards). Altematively radiosurgery can allow dose escalation (example: from 13 to 20 Gy) for higher cure rates while maintaining the same complication rate as radiotherapy with a 15-mm treatment margin (first arrow pointing upwards). The complication curves were estimated from the RTOG radiosurgery doseescalation data (16) for brain metastases <2 cm in diameter (lower curve) and 3-4 ern in diameter (middle curve). Since more normal tissue will be irradiated when treating with a margin versus treating a larger tumor. the middle curve most likely underestimates the complication risk.
The Linear-quadratic Formula
The linear-quadratic formula is a way of representing the effect of radiotherapy to account for the effects of different fractionation schemes 0-4). It proposes that cell survival after a dose of ionizing radiation follows a combination of single-hit or linear kinetics (seemingly representing doublestranded DNA breaks) and double-hit kinetics represented by a quadratic term (seemingly representing single-stranded DNA breaks). For single-fraction irradiation, the probability of curing a tumor or a normal tissue injury is represented by the following probabilistic double-exponential equation: P (cure or complication) = EXP[-K-EXP(-alpha·dosebeta-dose-j]
[1]
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Where P is the probability of cure or complications, EXP represents the number e (2.7183, commonly used in natural logarithms) raised exponentially to the power of the terms that follow; K represents the number of clonogens, while alpha and beta are coefficients for the respective single-hit and double-hit components.
This formula can be used to describe sigmoid-shaped doseresponse curves for the probability of cure or complications increasing with dose from 0% eventually up to 100% ( Figure I ).
The ratio of the alpha to the beta coefficients (the alpha/beta ratio) can be used to estimate the effect of a course of fractionated radiotherapy schedule administered with certain dose per fraction in terms of an equivalent dose for treatment with another dose per fraction. Different tumors and different normal tissue reactions have different alphalbeta ratios. Studies of the effects of fractionated radiotherapy in the clinic and in animal models found that late responding tissues such as brain or spinal cord have alphalbeta ratios around 2.
For rapidly responding tissues such as skin or mucosal erythema reactions, alphalbeta values are usually 5-8, while many fast-growing malignant tumors have values closer to 10 0,4). Low radiation dose-fractions cause proportionally less injury to tissues or tumors with a low alpha/beta ratio (a smaller alpha or single-hit component to radiation cell-kill kinetics) compared to tissues or tumors with higher alphalbeta ratios.
The concept that tumors always have a higher alpha/beta ratio than normal tissue, so that fractionation always reduces radiation injury to nonnal tissue compared to tumors is erroneous. There is a wide variation of alpha/beta ratios found in malignant tumors. Some malignant tumors such as melanoma or prostate cancer (or at least some strains of them) have lower alpha/beta ratios than surrounding normal tissues (skin or rectumlbladder), supporting the use of larger dose-fractions for treatment (5) .
The normalized tolerance dose (6) at 2 Gy per fraction, NTD 2 (the equivalent total dose if given in a course with daily 2 Gy fractions) can be given by the following simplified equation: predicts that a IO-Gy single-fraction dose to the optic chiasm should have the equivalent effect of 32 Gy or 50 Gy at 2 Gy per fraction respectively for alphalbeta = a or 2, respectively. Using an alphabeta value of zero, the equivalent dose at 2-Gy per fraction for the 9.7 Gy radiosurgery-dose that caused optic neuropathy is only 47 Gy. From clinical experience with fractionated radiotherapy of pituitary adenomas and other parasellar tumors, the risk of optic neuropathy for 46-48 Gy at 2 Gy per fraction should be approximately 11300 (8) . The Harvard-Pittsburgh study and other clinical experiences with radiosurgery suggest that the equivalent effect for high-dose single fractions is greater than that predicted by the linear-quadratic formula, even when an alpha/beta value of zero is used (which stretches the theoretical basis of the formula).
The linear-quadratic formula has been found to be reasonably reliable in the laboratory and the clinic for extrapolating from one course of fractionated radiotherapy to another with different sized dose-fractions, as long as the dose-fractions stay in the range of 1-8 Gy. Extrapolating from conventional radiotherapy with 1.8-2.0 Gy fractions to the high doses of single-fraction irradiation used in radiosurgery is something different altogether. Table I takes common single-fraction radiosurgery doses and gives the predicted equivalent doses for fractionated radiotherapy with 2-Gy fractions (NTD 2 ) using alphalbeta values of 10 early-reacting tissues and 2 for late-reacting tissue (which is the accepted value for brain tissue). The last column provides dose-equivalent dose calculations using an alphalbeta value of zero (specifically, alpha =0), making it a quadratic exponential formula rather than a true linear-quadratic formula. The NTD 2 value using an alpha/beta value of zero is given by the formula below:
Equivalent dose (cxlP =0) for 2-Gy fractions = 1/ 2 (single fraction dose)2 [3] Using an alpha/beta value of zero is quite a stretch from the theoretical basis of the formula, which presupposes some contribution with single-hit kinetics (the alpha component) corresponding to direct double-stranded DNA breakage.
Optic Nerve Tolerance Doses for Radiosurgery
After analyzing optic nerve complications in a combined Harvard/University of Pittsburgh study of radiosurgery complications, we recommended 8 Gy as the recommended safe dose-limit for the optic nerves/chiasm (7) . The lowest optic chiasm dose at which radiation induced optic neuropathy developed in that study was 9.7 Gy. According to Table I , the linear-quadratic formula with values of 0 and 2 for alpha/beta
Dose-Response Analysis for Cranial Neuropathies after Acoustic Neuroma Radiosurgery
The linear-quadratic formula also runs into problems in describing single-fraction dose-response curves for radiosurgery. The values of alpha, beta, and the alpha/beta ratio should be able to be derived from the shape of the single-fraction dose-response curve. The single-fraction dose-response curves for injury to the facial and acoustic nerves after acoustic neuroma radiosurgery should allow calculation of alpha/beta ratios for radiation injury to these nerves. We analyzed 218 acoustic neuroma patients who underwent radiosurgery at the University of Pittsburgh from 1987-1997 with more than two years of followup. This analysis assumed that the dose to the facial and auditory nerves matched the marginal doses prescribed at the time of radiosurgery, since these nerves invariably lie along the capsule ofthe tumor. This assumption is not as reliable for the dose to the trigeminal nerve; the dose to the trigeminal nerve may be dramatically lower than the marginal dose for intracanalicular tumors. We found extremely small, negative beta coefficient values for facial and auditory neuropathy, with best-fitting alpha/beta ratios in the range of -30 to -55 ( Figure 2 and Table  II ). Not only does this not match with the expected value of alpha/beta =' 2, the negative values for beta and the alpha/beta ratios which mathematically describe the empirically best-fitting dose-response curves for this data are disallowed by the theoretical rationale for the linear-quadratic formula.
Radiobiological Analysis ofAVM Obliteration
We found similar difficulty fitting linear-quadratic doseresponse curves to data from radiosurgery of arteriovenous malformations (AVM). We studied obliteration after Gamma knife radiosurgery in 351 AVM patients with 3-11 years of follow-up imaging after Gamma Knife radiosurgery at the University of Pittsburgh between 1987-1997 (9) . The median marginal dose Flickinger et at. 
empirically fitted maximum obliteration rate to the dose-response function. Since it requires only data on overall obliteration, it bypasses any potential error in determining whether persistent AVM nidus lies within the original radiosurgery treatment volume. The maximum obliteration rate without embolization was narrowly defined at 87.9 ± 4.9% (p<O.OOOI). The additional risk of marginal miss due to embolization was 16.4 ± 7.6% (p=0.03). This model was less sensitive to the value of alphalbeta, so its value could not be precisely defined. The alphalbeta ratio value converged to zero (0 ± 13) when constrained to positive values, but unlike the data for in-field obliteration, an adequate fit was achieved at that value.
T2-weighted MR sequences will show new areas of increased signal change developing in areas of brain adjacent to AVM in approximately 30% of patients within two years after radiosurgery. This reaction, termed post-radiosurgery imaging changes, represents a radiation injury reaction affecting sur-roun~ing brain. It is symptomatic in 1/3 patients developing this reaction (10% of all AVM patients). Whether or not these changes produce noticeable symptoms varies dramaticallỹ epending on the region of brain affected. Because modeling the mfl~ence of location is extremely complex (10), evaluating postradiosurgery injury reactions (which did not seem to vary with location) represent a good endpoint for radiobiological analysis of radiation injury to the brain parenchyma after radiosurgery.
We used the linear-quadratic equation to model post-radiosurgery injury reactions using a database of 307 AVM patients with more than two years of follow-up after radiosurgery at the University of Pittsburgh. We identified postradiosurgery injury reactions in 87/307 of these patients; 32 were symptomatic. Equation [1] was used to model the probability of post-radiosurgery imaging reaction. We modeled the total number of c1onogens as the number of clonogens per ml times the treatment volume. We used marginal dose (minimum AVM nidus dose prescribed) to represent dose. As shown in Table II , the best-fitting value of alphalbeta value with non-linear regression analysis was -29.7 ± 2.4. Although marginal dose is a simplified way to represent the inhomogenous dose distribution to the surrounding normal tissue, the alpha/beta value obtained was consistent with those for facial and auditory neuropathies. was 20 Gy (range: 12-30) and median treatment volume was 5.7 cc (~ge: 0.26-24). We documented obliteration by angiography In 193/264 (73%) AVM, and by MR alone in 75/87 (86%) AVM for a 75% corrected obliteration rate. Because a portion of the AVM nidus may be unintentionally omitted from the treatment volume due to poor visualization at radiosurgery, it makes more sense to define a radiobiological dose-response analysis upon in-field nidus obliteration (whether or not there was obliteration within the treatment volume). We identified infield nidus obliteration in 220/264 (83.3%) patients with followup angiography and 54/351 (83.5%) patients using either angiographic or MR criteria for obliteration.
We also proposed an alternative maximum obliteration rate model for the dose-response of AVM obliteration using overall obliteration as the endpoint. This model adds añ e best-fitting values of alphalbeta for angiographic obliteranon and for MR plus angiographic obliteration for empirically derived logistic regression models were alP = -44.4 ± 12.5 and alP = -45.3 ± 9.8, respectively. While the values derived using standard linear-quadratic Poisson models which were: alP =-48.1 ± 5.9 for angiographic obliteration only and alP = -49.3 ± 5.3 for MR or angiographic obliteration. Figure 3 shows the dose-response curve for in-field MR or angiographically-defined obliteration. The negative alphalbeta ratio was necessary to mathematically describe the plateau in the dose-response curve (at approximately 23 Gy).
Figure2: L~near-quadratic
(Poisson) dose-response curves for the development of auditory and facial neuropathies according to marginal (minimum tumor) dose. These curves and their corresponding alpha/beta ratio values were obtained from nonlinear.regresslon analysis of 218 acoustic neuroma patients who underwent radiosurgery at the University of Pittsburgh from 1987-1997 with more than two years of follow-up.
Comparison of Post-radiosurgery Injury Reactions for AVM Compared with Meningioma
We analyzed post-radiosurgery imaging changes (symptomatic or asymptomatic edema) that developed in 27/307 AVM patients, compared to 14/291 meningioma patients with two or effects of the target tissue. The higher risk of an injury reaction in treating AVM compared to meningioma indicates that the injury reaction to the target vasculature may affect the surrounding normal tissue and its supporting vasculature. The RTOG Radiosurgery Dose-Escalation Study (95-05) was a landmark study that yielded a number of important findings (II). 156patients with recurrent brain metastases or primary tumors (brainstem excluded) were prospectively treated according to a dose escalation protocol stratified by lesion diameter (16). Starting withinitial doses of 18, 15,and 12 Gy for diameters <20,21-30, and 31-40mm respectively, doses were escalated in 3 Gy intervals until toxicity was seen in over 30 % of patients. The next lowest dose before reaching >30 % toxicity was defined as the maximum tolerated dose(MTD). In the patient group withtumors <20 mm, toxicity neverexceeded 30 %. Figure 4 showsthe reported lateneurological toxicity data at each diameter that fitted to logistic dose-response curves. These curves allow doses for different risk levels to be estimated. We usually do not exceed the doses listed in Figure 4 estimated to havea 10% riskof lateneurological sequelae for radiosurgery immediately following whole brain radiation. Table III shows the results of a multivariate logistic regression comparison of AVM versus meningioma with a modelcontrolling for the effects of dose (in a linear quadratic expression with marginal dose and marginal dose squared) and for treatment volume. The chanceof developing a post-radiosurgery imaging changes was significantly higher (P<O.OOOI) in the AVM patients by a factorof7.5 (95%confidence interval: 3.4-16.4). The ratio of the regression coefficients for marginal dose and marginal dose squared yielded an approximated alpha/beta ratio of -42.2 ±17.2.
Reanalysis of this data using symptomatic post-radiosurgery injury only as the endpoint gave similar results. We found AVM had a significantlyhigher (P=O.04) risk of symptomatic sequelae by a factor of 2.58 (95% confidence interval: 1.04-6.41). The approximate value of alpha/beta was -42.0 ±26.7. Figure 4 : Logistic dose-response curves fit to the late toxicity data reported for the RTOG Radiosurgery Dose-Escalation Study. The numbers refer to the number of tumors treated at each dose level for each size category (stars <20 mm, squares 21-30 mrn, diamonds 31-40 mm). The doses where 10 % late toxicity occurs in the filled curves are shown next to the legend.
Discussion
These comparisons of post-radiosurgery imaging changes and symptomatic sequelae in AVM versus meningiomaradiosurgerytarget tissuesdemonstratethat the target tissue affects the chance of developinga radiation injury reaction. Normal Tissue Complication Probability models calculate injury relate based only on the dose of radiation received by the tissue or organs surrounding the tumor or target and ignore the Radiobiological analysis of clinical data led to a number of conclusions: 1. The linear-quadratic equation cannot reliably estimate equivalent radiation effects for extrapolating from conventional fractionation to the high-dose (12-25 Gy) single-fractions of radiation commonly used in radiosurgery.
2. Models of radiation injury need to take into account that the target or tumor tissue reaction to radiation may affect the reaction of the surrounding normal tissue. Normal tissue reactions do not depend only on the dose distribution to the surrounding normal tissue. 3. Much of the radiation injury response of a radiosurgical target is mediated through the target or tumor vasculature.
With respect to the first conclusion, we found a consistent inability of the linear-quadratic equation to fit the clinical data from radiosurgery. The inability to predict a safe dose for single-fraction radiation by extrapolating from the wealth of experience with fractionated radiotherapy (Table 1) is quite convincing. We consistently found high negative values for the alphalbeta ratio from auditory neuropathy, facial neuropathy, AVM obliteration, and post-radiosurgery imaging changes which should be unallowable with the linear-quadratic formula. These negative alphalbeta models only make sense as parameters for fitting the shape of the dose-response curve within the range of doses being examined. The model with auditory neuropathy is the strongest of the group. The dose estimates to the auditory nerve should reliably correspond to the marginal dose and the greater sensitivity of the auditory nerve to injury makes it a sensitive model for evaluation. One could object to the fact that the analyses of AVM obliteration and post-radiosurgery injury reaction use the marginal dose for simplicity rather than the entire dose-volume histogram, but the fact that these findings are consistent with the better models of optic, facial, and auditory neuropathies provide further reason to doubt the ability of the linear-quadratic formula to hold up to the extreme of radiosurgical doses.
We reached the second and third conclusions when we showed that the risks of post-radiosurgery imaging changes and of symptomatic post-radiosurgical sequelae were significantly higher for AVM targets than meningiomas. This means that the target tissue must contribute to the reaction otherwise the injury risks should be' the same for the same doses with the same treatment volumes. The multivariate model which included the treatment volume and a linearquadratic expression of marginal dose should have adequately controlled for dose-volume effects. We previously analyzed our AVM data with dose threshold models for postradiosurgery imaging changes, looking at the volume of target or surrounding normal receiving 8. 10, or 12 Gy or more. We found that the best-fitting model was with the total volumeof tissue receiving >12 Gy, rather than models that excluded the target tissue and were based on the volume of the surrounding normal tissue receiving the threshold dose or higher. If the target contributes to the radiation response of the surrounding tissue, tqjs needs to be taken into account in any model for predicting normal complication probability.
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Our finding of a dramatically higher rate of post-radiosurgery imaging changes and symptomatic sequelae in AVM compared to meningioma leads to the conclusion that the target vasculature is responsible for much of the injury response to radiosurgery. The nidus of an AVM contains more of this reacting vascular tissue than any other non-vascular target and therefore would react more strongly to radiation injury. The fact that tumors with high alphalbeta ratios like glioblastomas and brain metastases respond to radiosurgery much better than expected (with glioblastoma responses equivalent to high-dose brachytherapy) suggest that the tumor vasculature. which should be a late-responding (low alpha/beta ratio) tissue is responsible. Pathological studies of tumors resected after radiosurgery indicate that vascular endothelium may be the primary target responding to radiosurgery (12) .
